Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
Status:
Recruiting
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of parsaclisib plus the standard
drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate,
and prednisone [R-CHOP]) and to see how well they work compared with R-CHOP alone in treating
patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab
is a monoclonal antibody that may interfere with the ability of cancer cells to grow and
spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and
vincristine sulfate, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used
with other drugs in the treatment of some types of cancer. It is not yet known if giving
parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high
risk diffuse large B-cell lymphoma.